Tsuchiya Tomoshi, Hashizume Satoshi, Akamine Shinji, Muraoka Masashi, Honda Sumihisa, Tsuji Koichi, Urabe Shougo, Hayashi Tomayoshi, Yamasaki Naoya, Nagayasu Takeshi
Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Japan.
Chest. 2007 Jul;132(1):170-7. doi: 10.1378/chest.06-1950. Epub 2007 May 15.
There is a need for a more complete classification system of lung cancer. To address this issue, we assessed whether the new staging could differentiate patients with early-stage cancers who have poorer prognosis and improve the unbalanced patient numbers with overlapping prognoses arising from the current TNM staging system.
The study included 995 patients with pathology stages I and II non-small cell lung cancer (NSCLC) who underwent surgical resection at two institutions. We subclassified patients with stage IA and IB NSCLC based on the presence of vessel invasion (Vi). Stage IA Vi and stage IB non-Vi were combined into new stage IB, as were stages IB Vi and IIA into new stage IIA.
The numbers of patients of stages IA, IB, IIA, and IIB were 477, 314, 55, and 149, and their 5-year survival rates were 86.0%, 66.2%, 60.7%, and 50.4%, respectively. Vi groups showed significantly poorer prognosis than non-Vi groups at stage IA (p = 0.011) and at stage IB (p = 0.036). The numbers of patients of new stages IA, IB, and IIA were 333, 260, and 253, and their 5-year survival rates were 88.7%, 76.4%, and 61.2%, respectively. Regression analysis indicated that the new staging improved predictability of overall survival according to disease stage, and Akaike information criterion (3023.7) was significantly lower than that for current staging system (3032.5).
Upstaging of Vi groups allows differentiation of patients with early-stage cancers with poor prognosis and improves the unbalanced numbers of patients and prediction of prognosis in cases of lung cancer.
需要一个更完善的肺癌分类系统。为解决这一问题,我们评估了新的分期系统能否区分预后较差的早期癌症患者,并改善当前TNM分期系统导致的预后重叠患者数量不均衡的情况。
该研究纳入了995例在两家机构接受手术切除的病理分期为I期和II期的非小细胞肺癌(NSCLC)患者。我们根据血管侵犯(Vi)情况对IA期和IB期NSCLC患者进行了亚分类。IA期有Vi的患者和IB期无Vi的患者合并为新的IB期,IB期有Vi的患者和IIA期患者合并为新的IIA期。
IA期、IB期、IIA期和IIB期的患者数量分别为477例、314例、55例和149例,其5年生存率分别为86.0%、66.2%、60.7%和50.4%。在IA期(p = 0.011)和IB期(p = 0.036),有Vi的组预后明显比无Vi的组差。新的IA期、IB期和IIA期的患者数量分别为333例、260例和253例,其5年生存率分别为88.7%、76.4%和61.2%。回归分析表明,新的分期系统提高了根据疾病分期对总生存的预测能力,赤池信息准则(3023.7)显著低于当前分期系统(3032.5)。
有Vi组的分期上调能够区分预后较差的早期癌症患者,并改善肺癌患者数量不均衡的情况以及预后预测。